One review analyzes the evidence that supports the role played by the endocannabinoid system in the neuro-inflammatory state in the disorder associated with the autism spectrum.
A review of available preclinic and clinical information found that the endocannabinoid system may create conditions to reduce inflammations commonly characterized in Autism Spectrum Disorder (ASD).
The latest research is hypothesizing a link between the onset of the main behavioral symptoms of ASD and the chronic neuro-inflammatory condition of the autistic brain; growing evidence of this connection is shedding light on new potential actors in the pathogenesis of ASD.
The review was carried out by researchers from the Department of Sciences, Biomedical and Technological Sciences of the University of Rome III.
“The endocannabinoid system (ECS) plays a key role in neurodevelopment as well as normal inflammatory responses and it is not surprising that many preclinical and clinical studies explain alterations in endocannabinoid signaling in ASD.”
This finding surprised researchers who claim to now have a greater understanding of the neurochemical mechanisms around ASD. And in short it shows how cannabinoids can be highly recommended for pathologies within the autism spectrum for their famous anti-inflammatory properties.
“This review analyzes current preclinic and clinical evidence supporting a key role of ECS in the neuro-inflammatory state that characterizes ASD, providing clues to identifying new biomarkers in ASD and promising therapies for the future,” the study concludes.
Read the report: https://pubmed.ncbi.nlm.nih.gov/33358985/
in Costa Rica. 
